CD4 and neoplasm: Furthermore, these levels of both CD4+CD25+ and CD25+Foxp3+ cells in (rapamycin + SK-TCL-mDC)-treated mice were quite comparable to the levels detected in normal (i.e., not tumor-bearing) mice (i.e., 3.4% and 0.4%, respectively).